Giant scrotal lymphedema after paraffinoma injection: A case report

Scrotal lymphedema is a rare condition characterized by blocked lymphatic drainage to the scrotum, resulting in physical and psychological discomfort for sufferers. Here, we present a case study of a 27-year-old male with giant scrotal lymphedema resulting from paraffinoma injection. The patient experienced scrotal enlargement since 2019, which engulfed the penis and was surrounded by edema. After confirming the absence of filariasis parasites, the patient underwent paraffinoma excision and scrotoplasty, resulting in a 13 kilograms scrotal specimen with no signs of malignancy. Giant scrotal lymphedema can be distressing, but surgical excision can improve the patient's quality of life.

The Role of Docetaxel in Non-Castrate Resistant Metastatic Prostate Cancer: An Evidence-based Case Report

AIM

to learn the role of docetaxel in non-castrate resistant prostate cancer patient.

METHODS

literature search was conducted to find relevant study comparing the combination of docetaxel and androgen deprivation therapy (ADT) to ADT alone in non-castrate resistant prostate cancer using PubMed, Cohrane Library, Proquest, EBSCO, and Scopus database. Quality assessment of studies was done using Bond University Rapid Critical Appraisal of a Systematic Review.

RESULTS

we found 494 studies from literature search, but only two studies were included in final selection. Based on validity assessment, we chose one study to be discussed further. This study showed that combination of docetaxel and ADT is better than ADT alone in regards of overall survival (HR 0.64; 95% CI 0.55, 0.75; p<0.0001; NNT=3), biochemical progression free survival (HR 0.63; 95% CI 0.57, 0.69; p<0.0001; NNT=2) and clinical progression free survival (HR 0.73; 95% CI 0.64, 0.84; p<0.0001; NNT=2). Benefit of docetaxel and ADT combination was especially seen in high volume disease (HR 0.67; 95% CI 0.54, 0.83; p=0.0003; NNT=3).

CONCLUSION

addition of docetaxel into ADT has beneficial effects in terms of overall survival and progression free survival in patients with non-castrate resistant metastatic prostate cancer.